D. Wesół-Kucharska, M. Greczan, M. Kaczor, E. Ehmke Vel Emczyńska-Seliga, M. Hajdacka, E. Czekuć-Kryśkiewicz, D. Piekutowska-Abramczuk, P. Halat-Wolska, E. Ciara, M. Jaworski, A. Jezela-Stanek, et al. (2024). Efficacy and Safety of Ketogenic Diet Treatment in Pediatric Patients with Mitochondrial Disease. Nutrients, 16(6). https://doi.org/10.3390/nu16060812

PubMed 38542723

[Abstract]
Mitochondrial diseases (MDs) are a heterogeneous group of disorders resulting from abnormal mitochondrial function. Currently, there is no causal treatment for MDs. The aim of the study was to assess the effectiveness and safety of the ketogenic diet (KD) in patients with MD and to analyse selected biochemical and clinical parameters evaluating the effectiveness of KD treatment in patients with MDs. A total of 42 paediatric patients were assigned to four groups: group 1-patients with MD in whom KD treatment was started (n = 11); group 2-patients with MD remaining on an ordinary diet (n = 10); group 3-patients without MD in whom KD treatment was initiated (n = 10), group 4-patients without MD on a regular diet (n = 11). Clinical improvement was observed in 9/11 patients with MD treated with KD. Among patients with MD without KD, the clinical condition deteriorated in 7/10 patients, improved in 2/10 patients, and remained unchanged in one patient. Adverse events of KD occurred with a comparable frequency in groups 1 and 3. There was no significant difference in changes in biomarker concentrations over the course of the study among patients treated and untreated with KD.